Gold prices edge higher on raised Fed rate cut hopes
Investing.com - Citizens JMP has reiterated its Market Outperform rating on Rapport Therapeutics (NASDAQ:RAPP) with a price target of $28 ahead of upcoming clinical trial results. With a current market cap of $439.43 million and trading at $12.04, the stock has declined 32% year-to-date, though InvestingPro data shows the company maintains a strong balance sheet with more cash than debt.
The firm expects Rapport to report top-line results in September from its Phase 2a trial evaluating RAP-219 in adults with refractory focal epilepsy, identifying this as one of two high-conviction clinical catalysts in its coverage for the third quarter of 2025.
Citizens JMP expressed confidence in the potential for positive results, citing the validated mechanistic rationale, supportive preclinical data, and target engagement/proof-of-pharmacokinetics for the epilepsy treatment candidate.
The firm estimates potential upside of more than 100% for Rapport stock if the trial yields positive results, which it assigns a 68% probability of occurring.
Conversely, Citizens JMP projects a 50-75% downside for the stock in the event of definitively negative results, a scenario it considers 32% probable.
In other recent news, Rapport Therapeutics has been the focus of several analyst updates, primarily revolving around its developmental drug, RAP-219. TD Cowen has reiterated its Buy rating for Rapport Therapeutics, expressing optimism about the upcoming data release in September for the RAP-219 trial targeting focal onset seizures. Jones Trading also maintained its Buy rating, with a price target of $42.00, following the company’s Investor & Analyst Day, where positive expectations for the Phase IIa results were discussed. Stifel analysts reaffirmed their Buy rating, setting a price target of $35.00, citing the strong concordance rate between long episodes and EEG seizures in the RAP-219 study. Similarly, Citizens JMP analysts upheld a Market Outperform rating with a $28 price target, highlighting the potential of RAP-219 as a promising neurotherapy. The company has successfully completed enrollment for the trial, and proof-of-concept results are expected to be revealed soon. These developments underscore the ongoing confidence among analysts in Rapport Therapeutics’ research and development efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.